{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:24:45Z","timestamp":1761171885842,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":4494,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.farma.2009.09.003","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T02:14:22Z","timestamp":1264385662000},"page":"23-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influencia del tiempo de perfusi\u00f3n de pamidronato en la funci\u00f3n renal de pacientes con mieloma m\u00faltiple"],"prefix":"10.1016","volume":"34","author":[{"given":"F.","family":"Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Barreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mole\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2009.09.003_bib1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"The Oncologist"},{"key":"10.1016\/j.farma.2009.09.003_bib2","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/1097-0142(20000615)88:12+<3022::AID-CNCR19>3.0.CO;2-R","article-title":"Bisphosphonates in multiple myeloma","volume":"88","author":"Kanis","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2009.09.003_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.12-1-62","article-title":"The use of bisphosphonates in elderly cancer patients","volume":"12","author":"Gridelli","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/j.farma.2009.09.003_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/107327489900600302","article-title":"Bisphosphonates in the management of breast cancer","volume":"6","author":"Cristofanilli","year":"1999","journal-title":"Cancer control"},{"key":"10.1016\/j.farma.2009.09.003_bib5","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2009.09.003_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in qreducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2009.09.003_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.farma.2009.09.003_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.farma.2009.09.003_bib9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.farma.2009.09.003_bib10","unstructured":"Ficha t\u00e9nica de Aredia\u00ae [consultado12\/11\/2008]. Disponible en: https:\/\/sinaem4.agemed.es\/consaem\/especialidad.do?metodo=verFichaWordPdf&codigo=62132&formato=pdf&formulario=FICHAS"},{"key":"10.1016\/j.farma.2009.09.003_bib11","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology 2007 Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464\u201372.","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"10.1016\/j.farma.2009.09.003_bib12","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. Disponible en: http:\/\/ctep.cancer.gov."},{"key":"10.1016\/j.farma.2009.09.003_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.farma.2009.09.003_bib14","unstructured":"Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bifosfonatos para el mieloma m\u00faltiple (Revisi\u00f3n Cochrane traducida). En: La Biblioteca Cochrane Plus, n\u00famero 3.. Oxford: Update Software Ltd.; 2008. Disponible en: http:\/\/www.update-software.com."},{"key":"10.1016\/j.farma.2009.09.003_bib15","first-page":"95","article-title":"Insuficiencia renal \u201coculta\u201d por valoraci\u00f3n de la funci\u00f3n renal mediante la creatinina s\u00e9rica","volume":"22","author":"Fern\u00e1ndez-Fresnedo","year":"2002","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.farma.2009.09.003_bib16","first-page":"S84","article-title":"Plasma creatinine greatly underestimates the degree of renal function impairment in elderly inpatients","volume":"21","author":"Strocchi","year":"2003","journal-title":"J of Hypertens"},{"key":"10.1016\/j.farma.2009.09.003_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/16.5.1042","article-title":"Screening for renal disease using serum creatinine. What are we missing?","volume":"16","author":"Duncan","year":"2001","journal-title":"Nephrol Dial Transplant"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634309000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634309000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:14:52Z","timestamp":1761106492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634309000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1130634309000142"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2009.09.003","relation":{},"ISSN":["1130-6343"],"issn-type":[{"type":"print","value":"1130-6343"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influencia del tiempo de perfusi\u00f3n de pamidronato en la funci\u00f3n renal de pacientes con mieloma m\u00faltiple","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2009.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 SEFH. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}